Engineered insulins · diabetes
Insulin analogs are versions of human insulin with a few amino acids changed or added so they act faster or longer after injection. Rapid-acting analogs (lispro, aspart, glulisine) cover the rise in glucose after eating; long-acting analogs (glargine, detemir, degludec and the newer icodec) supply steady background insulin. All are prescription diabetes treatments.
Like the body's own insulin, every analog activates the insulin receptor. That moves glucose into muscle and fat, stops the liver from releasing glucose, and slows the breakdown of fat and protein1,2. What differs is how the injected insulin is absorbed.
In insulin lispro, two neighboring amino acids near the end of the B chain (proline and lysine at B28 and B29) are swapped; it is absorbed more quickly than regular human insulin, starts working sooner and wears off sooner1. Insulin glargine has one amino acid replaced and two arginines added; it is absorbed slowly from under the skin, giving a relatively flat level over about a day with no pronounced peak, compared with older NPH insulin2. The point of these changes is to match insulin to the body's needs more predictably.
In the trials summarized here, both comparing long-acting insulins, the clearest difference was fewer low-blood-sugar episodes rather than better average glucose. In the 24-week Treat-to-Target trial, 756 overweight adults with type 2 diabetes added glargine or NPH insulin to their tablets; both reached the same HbA1c (about 7.0%), but rates of symptomatic hypoglycemia were 21-48% lower with glargine and more people reached target without nighttime lows3.
In the double-blind DEVOTE trial, 7,637 people with type 2 diabetes at high cardiovascular risk received degludec or glargine; major cardiovascular events were similar (8.5% versus 9.3%, meeting non-inferiority), and severe hypoglycemia was less common with degludec (4.9% versus 6.6%)4. Both trials compared one insulin with another, so benefits are relative to older insulins, not to no treatment.
The FDA has approved many insulin analogs to improve blood-sugar control in diabetes, starting with insulin lispro (Humalog) in 1996 and followed by glargine and aspart, glulisine, detemir, degludec, several follow-on and biosimilar versions, and, in 2026, insulin icodec (Awiqli) for adults with type 2 diabetes1,2,5.
Low blood sugar is the main risk and can be life-threatening; labels warn that any change in insulin type, strength, manufacturer, injection site or method needs closer glucose monitoring1,2. Other listed reactions include allergic reactions, which can be severe, injection-site reactions, lipodystrophy (changes in fat under the skin), itching, rash, low potassium, swelling and weight gain. Accidental mix-ups between insulin products can occur, and pens or cartridges must never be shared, even with a new needle.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.
Brand names on this page belong to their owners and are used only to identify a product. goodtides is not affiliated with those companies.